

Evaluation of the Effectiveness of a Xospata Routine Risk Minimisation Measure (RMM) and an Additional Risk Minimisation Measure (aRMM): A Cross-sectional Survey Study among Healthcare Professionals to Assess Awareness and Knowledge

First published: 02/07/2021

Last updated: 02/07/2024

Study

Finalised

Administrative details

EU PAS number

EUPAS37354

Study ID

50133

DARWIN EU® study

No


Study countries

 Czechia

 France

 Germany

 Italy

 Netherlands

 Sweden

Study description

This study will assess the awareness and knowledge of three selected safety concerns (Posterior Reversible Encephalopathy Syndrome PRES, QT prolongation, and Differentiation Syndrome DS) among HCPs. The primary objective is to describe HCPs' awareness and knowledge of the three selected safety responses (PRES, QT prolongation, and DS) associated with Xospata use. The secondary objective is to assess the percentage of HCPs that recall receiving and/or reviewing the Xospata routine RMM (SmPC) and the Xospata aRMM (HCP educational materials).


Study status


Finalised

Research institutions and networks

Institutions

ICON Commercialisation & Outcomes

 Germany

 Ireland

First published: 19/03/2010

Last updated: 05/07/2024

Institution

Non-Pharmaceutical company

ENCePP partner

Contact details

Study institution contact

Registration Department Clinical Trial
clinicaltrialregistration@astellas.com

Study contact

clinicaltrialregistration@astellas.com

Primary lead investigator

Kimball Samantha

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 20/03/2020

Study start date

Planned: 08/07/2021

Actual: 30/09/2021

Data analysis start date

Planned: 09/07/2022

Actual: 17/08/2022

Date of final study report

Planned: 11/11/2022

Actual: 21/11/2022

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Astellas

Study protocol

[Xospata_NI-PASS Protocol_v2.0_09Dec2020 Redacted.pdf](#) (1.95 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Other study registration identification numbers and links

2215-PV-0001

Methodological aspects

Study topic:

Other

Study topic, other:

Disease/Epidemiology study

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

Data collection methods:

Primary data collection

Main study objective:

The main objective of the study is to describe HCPs' awareness and knowledge of the three selected safety concerns (PRES, QT prolongation, and DS) associated with the use of Xospata and to assess percentage of HCPs that recall receiving and/or reviewing Xospata routine RMM (SmPC) and the Xospata aRMM (HCP educational materials).

Study Design

Non-interventional study design

Cross-sectional

Other

Non-interventional study design, other

Population studied

Short description of the study population

A survey of health care professional, specifically those who specialize in blood diseases including hematologists and hematooncologists prescribing Xospata in the participating Europe countries (Czech Republic, France, Germany, Italy, Netherlands, and Sweden).

Inclusion Criteria:

1. HCPs who treat patients diagnosed with leukemias, including AML, who can prescribe Xospata in the participating European countries, and
2. HCPs who provide permission to share their responses in aggregate with the EMA and/or the NCAs

Exclusion Criteria:

1. HCPs who participated in the cognitive pre-testing of the survey, or
2. HCPs who have themselves or have immediate family members who have worked for Astellas, ICON (coordinating investigator), EMA, or the NCAs of the participating member states within the past 5 years.

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Estimated number of subjects

Study design details

Outcomes

The percentages of HCPs with correct responses to questions regarding knowledge of the three selected safety concerns (PRES, QT prolongation and DS) associated with the use of Xospata. The percentages of HCPs that recall receiving and/or reviewing the Xospata routine RMM (SmPC) and the Xospata aRMM (HCP educational materials).

Data analysis plan

A statistical analysis plan (SAP) will be developed to describe all planned analyses in detail, along with shells for variable lists, tables and figures to be produced. The study population included in the data analysis will include HCPs who completed at least one of the questions in the survey associated with the primary endpoints. Descriptive data analyses will be conducted. Levels of receipt, use, and knowledge will be calculated with 95% two-sided Confidence Intervals (CIs). These descriptive results will be reported for the overall population of respondents and by country, and for sub-groups such as HCP specialty, time since dissemination of HCP materials in each country, and history of prescribing Xospata, depending on the final distribution of data across these sub-groups. Additionally, a descriptive analysis of the characteristics of non-responders will be completed.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Invitations to participate will be targeted to 16,000 HCPs by either email or by post mail using available contact information with an anticipated response rate of approximately 2.5% (400 HCPs)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No